JFSA Transaction Reporting

Understand, validate and oversee Japan OTC derivatives reporting with confidence

Japan’s OTC derivatives reporting regime is designed to improve transparency, support supervisory oversight and strengthen the resilience of the derivatives market. The framework sits under the Financial Instruments and Exchange Act (FIEA) and requires certain in-scope entities to provide transaction information to a trade repository or designated foreign trade repository. The current harmonised reporting guidelines took effect on 1 April 2024.

For firms in scope, the challenge is not simply reporting data. It is demonstrating that reportable transactions have been identified correctly, that source data is complete and accurate, and that the control framework around reporting can withstand regulatory scrutiny.

What is Japan Reporting?

Japan reporting refers to the obligation to create, preserve and report OTC derivatives transaction information under the Japanese trade reporting regime. Under Articles 156-63 and 156-64 of the FIEA, financial instruments clearing organisations and financial instruments business operators or registered financial institutions must provide transaction information to a trade repository or designated foreign trade repository. The repository must then prepare and preserve records and report retained transaction information to the Prime Minister.

Japan introduced OTC derivatives trade reporting in 2013, and the framework has since been updated to reflect international harmonisation, including UTI, harmonised critical data elements and broader alignment with global reporting standards. The current detailed reporting guidelines reference international sources including CDE guidance and UTI harmonisation.

Who is required to report under Japan reporting?

Japan’s reporting framework applies to:

• financial instruments clearing organisations, including foreign financial instruments clearing organisations

• financial instruments business operators

• registered financial institutions

This means the regime is centred on regulated financial market participants rather than a broad corporate threshold model.

Scope and Japanese nexus

The Japanese framework applies to OTC derivatives transactions carried out by the relevant in-scope reporting entities under the Cabinet Office Order. In practice, scope depends on whether the reporting entity falls within the prescribed categories and whether the transaction is within the Japanese OTC derivatives reporting perimeter under the FIEA framework.

What must be reported?

Japan’s reporting framework requires reporting of a broad range of transaction information. The reporting guidelines list data elements including but not limited to:

• effective date

• expiration date

• early termination date

• reporting timestamp

• execution timestamp

• entity responsible for reporting

• reporting counterparty and counterparty identifiers

• UTI

• valuation amount, currency, timestamp and method

• collateral portfolio indicator

• initial margin and variation margin data

• other harmonised product and lifecycle information.

The framework has clearly moved toward internationally harmonised reporting content. The guidelines reference global standards and guidance, including UTI harmonisation, critical data elements, and technical specifications used in other major jurisdictions.

Reporting deadlines

Japan’s current guidance indicates that trade data must be reported to trade repositories within T+2 business days. The guidelines note that UTI should be shared promptly, ideally at execution, because the trade data must be reported within that T+2 period.

For firms in scope, that means reporting timeliness depends not only on submission capability, but also on prompt UTI creation, data availability and operational coordination across counterparties and internal systems. This is an inference from the reporting deadline and UTI guidance.

Is Japan reporting single-sided, dual-sided or delegated?

Japan reporting operates in practice as a dual-sided reporting framework, because each in-scope reporting entity has its own reporting obligation. Firms should analyse the legal reporting obligation based on the status of the Japanese reporting entity and the applicable transaction.

Operationally, firms may still rely on third parties, infrastructure providers or group reporting models, but accountability for compliance and reporting quality remains with the relevant reporting entity. That is an operational inference from the structure of the regime.

Are there Japan reporting exemptions or reliefs?

Japan does provide limited relief from part of the reporting obligation for smaller in-scope firms. The FSA states that if a reporting entity’s average  aggregate notional amount of certain OTC derivatives is  less than JPY 300 billion, and the required notification is made to the JFSA and the trade repository, then certain transactions arising during the relevant  period are exempt from the creation, preservation and reporting obligation. The relief applies  to OTC Financial Derivatives Transactions other than those that refer to an interest rate, debt securities or FX.

That means exemption analysis in Japan is not just about entity type - it can also depend on transaction volume thresholds and procedural notification steps.

Consequences of non-compliance

Japan’s reporting regime sits under the FIEA and is part of the supervisory framework for OTC derivatives transparency. The FSA publishes aggregated OTC derivatives transaction reports based on data reported by financial instruments business operators in Japan, underlining that this is an active regulatory reporting regime rather than a purely theoretical obligation.

For firms in scope, the expectation is that reported data is complete, timely and supportable. Weaknesses in scope determination, UTI handling, valuation, collateral reporting or control evidence can therefore create regulatory and operational risk, even where the immediate issue originates in source data or process design. This is an inference from the structure and operation of the reporting regime.

How En:ACT helps with Japan reporting oversight

En:ACT helps firms strengthen control over their Japan reporting obligations by ingesting raw transaction data from any source system, performing books and records reconciliation, and assessing 100% of transactions and fields against the applicable Japanese reporting rules.

Using transparent, regulator-linked logic, the platform identifies:

• eligibility issues

• field-level errors

• cross-field inconsistencies

• missing identifiers

• UTI issues

• valuation and collateral reporting gaps

• reporting anomalies

Each identified issue is linked directly to the specific Japanese reporting rule breached, giving firms a clear view of what is wrong, why it matters and where remediation is required.

En:ACT also ensures rules are kept up to date to reflect developments across:

• regulatory text

• regulator guidance

• consultation papers

• relevant industry papers

For Japan specifically, that means firms benefit from rule coverage maintained in line with the FIEA reporting framework, the Cabinet Office Order and the detailed JFSA reporting guidelines.

Specialist Japan expertise from the Novatus Intelligence team

Our Japan capability is supported by specialists within the Novatus Intelligence team, including SMEs with backgrounds across:

• banking

• asset management

• product

• regulation

For each regime, we align subject matter expertise to the specific rule set. In the case of Japan, that means access to specialists who understand the Japanese OTC derivatives reporting framework, the practical implications of the 1 April 2024 harmonised reporting changes, and the operational control challenges firms face in maintaining reporting quality over time.

This combination of regulatory interpretation and operational experience helps clients move beyond basic compliance and build a reporting framework that is accurate, scalable and defensible.

‍

Common Japan reporting challenges

Some of the most common Japan reporting issues include:

• incomplete or inconsistent source data

• weak entity and scope mapping

• delayed or inconsistent UTI generation and sharing

• valuation and collateral reporting weaknesses

• cross-field inconsistencies that only become visible when the full record is tested

• weak oversight of operational reporting models

In many cases, the issue is not a single bad field. It is the mismatch between the transaction as booked, the transaction as reported and the logic used to determine the final reported record. This is an inference from the data model and reporting structure in the JFSA guidelines.

‍

Why firms choose En:ACT for Japan reporting oversight

Firms use En:ACT because it gives them more than a validation tool. It provides a control framework around Japan reporting.

With En:ACT, firms can:

• test reporting quality against transparent rule logic

• reconcile source data to reported data

• identify issues before they become regulatory problems

• benchmark reporting quality over time

• evidence oversight of reporting operations

• prepare for rule changes with greater confidence

The result is stronger reporting assurance, better governance and a clearer line of sight from raw transaction data to regulatory submission quality.

‍